Recurrences and Deaths Prevented by Atezolizumab Translate to Lower Cost of Care
Adjuvant atezolizumab can prevent recurrence and death, thereby reducing costs, in patients with early non-small cell lung cancer, a study suggests.
Adjuvant atezolizumab can prevent recurrence and death, thereby reducing costs, in patients with early non-small cell lung cancer, a study suggests.
African-American women who survive breast cancer do not get adequate resources to support their mental and emotional health, a small study suggests.
Real-world data support first-line palbociclib plus an aromatase inhibitor as standard care for HR+, HER2- metastatic breast cancer, according to researchers.
Results of an ACCC study revealed advanced practitioners’ greatest challenges when treating cancer patients with combination IV/oral therapies.
Intermittent fasting appears safe as an adjunct to chemotherapy, but it is unclear whether this diet can improve cancer outcomes.